MET and neoplasm: In a study of 107 primary breast cancer patients, Hochgräfe and colleagues found higher phospho-c-Met expression (pY1234/5) in TN tumours [43], whereas Raghav and colleagues found no difference in phospho-c-Met expression (pY1235) between different molecular subtypes but did find higher recurrence rates in patients whose tumours showed high levels of pY1235 [44].